On December 7th, President Joe Biden’s administration proposed the potential use of march-in rights under the Bayh-Dole Act. This marks a pivotal moment in the landscape of drug pricing and healthcare. Xevant, a leader in healthcare analytics, is at the forefront of finding the equilibrium between making drugs affordable and fostering the continuous innovation crucial for medical advancements.

Leave a Reply

Your email address will not be published. Required fields are marked *